{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"}],"title":"Number of participants receiving cetuximab on study for ablation of CAR T cells"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}],"title":"Number of participants whose CAR T cells were successfully ablated by cetuximab administration"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"}],"units":"Participants"}],"description":"The efficacy of cetuximab to ablate the T cells will be measured by loss of detection of T cells and any associated toxicities as well as facilitating B cell recovery.","groups":[{"description":"This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\\^5 CAR T cells/kg","id":"OG000","title":"Phase 1 - Cohort 1A"},{"description":"This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\\^6 CAR T cells/kg","id":"OG001","title":"Phase 1-Cohort 1B"},{"description":"This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\\^6 CAR T cells/kg","id":"OG002","title":"Phase 1-Cohort 1C"},{"description":"This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\\^7 CAR T cells/kg","id":"OG003","title":"Phase 1-Cohort 1D"},{"description":"This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\\^5 CAR T cells/kg following prescribed lymphodepletion with fludarabine and cyclophosphamide","id":"OG004","title":"Phase 1-Cohort 1F1"},{"description":"This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\\^6 CAR T cells/kg following prescribed lymphodepletion with fludarabine and cyclophosphamide","id":"OG005","title":"Phase 1-Cohort 1F2"},{"description":"The phase 2 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\\^6 CAR T cells/kg following lymphodepletion if indicated","id":"OG006","title":"Phase 2"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Number of subjects receiving cetuximab on study for ablation of CAR T cells","reportingStatus":"POSTED","timeFrame":"3 years","title":"Number of Participants That Received Cetuximab Who Have T Cells Successfully Ablated","type":"SECONDARY","unitOfMeasure":"Participants"}